{"id":14633,"date":"2023-05-25T22:10:53","date_gmt":"2023-05-26T02:10:53","guid":{"rendered":"https:\/\/icesontario.wpengine.com\/?post_type=private_project&#038;p=14633"},"modified":"2025-02-28T12:06:12","modified_gmt":"2025-02-28T17:06:12","slug":"mantle-cell-lymphoma-mcl-associated-burden-of-illness-and-health-care-utilization-in-ontario","status":"publish","type":"private_project","link":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/mantle-cell-lymphoma-mcl-associated-burden-of-illness-and-health-care-utilization-in-ontario\/","title":{"rendered":"Mantle cell lymphoma (MCL): associated burden of illness and healthcare utilization in Ontario"},"content":{"rendered":"\n<p><strong>Client: <\/strong>IQVIA Solutions Canada Inc.<br><br><strong>Project ID:<\/strong> P2021-092 \/ 2022 0970 266 000<\/p>\n\n\n\n<p><strong>Research Question\/Objectives:<\/strong> MCL is generally considered incurable, and a relapse is almost universal. With the recent and imminent emergence of novel therapies for MCL (such as immune and targeted therapies), understanding the MCL patient profile, real-world treatment patterns, burden of illness (BOI), and outcomes among patients with newly diagnosed MCL in Canada is essential to inform decision making, especially in the context of aging population. To address this need, a retrospective, real-world study will be conducted for elderly MCL patients with a focus on those in the first-line (1L) setting.<\/p>\n\n\n\n<p><strong>Primary objective:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Describe the real-world BOI and key clinical outcomes for newly diagnosed MCL patients aged \u226565 at diagnosis.<\/li>\n<\/ul>\n\n\n\n<p><strong>Secondary objectives:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Describe the overall survival (OS) and time to next treatment (TTNT) for newly diagnosed MCL \u226565 patients in the 1st LoT with systemic therapies.<\/li>\n\n\n\n<li>Determine and characterize drug treatment patterns for newly diagnosed MCL \u226565 patients in the 1st LoT with systemic therapies.<\/li>\n\n\n\n<li>Compare HCRU and direct healthcare costs of newly diagnosed MCL \u226565 patients in the 1st LOT of systemic therapy to controls.<\/li>\n\n\n\n<li>Describe the incidence and prevalence of newly diagnosed MCL \u226565 population<\/li>\n<\/ul>\n\n\n\n<p><strong>Status<\/strong>: Completed<\/p>\n\n\n\n<p><strong>Results: <\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>April 2023<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Client: IQVIA Solutions Canada Inc. Project ID: P2021-092 \/ 2022 0970 266 000 Research Question\/Objectives: MCL is generally considered incurable, and a relapse is almost universal. With the recent and imminent emergence of novel therapies for MCL (such as immune and targeted therapies), understanding the MCL patient profile, real-world treatment patterns, burden of illness (BOI), [&hellip;]<\/p>\n","protected":false},"template":"","organization_type":[],"project_status":[105],"response_type":[],"class_list":["post-14633","private_project","type-private_project","status-publish","hentry","project_status-completed"],"acf":{"project_id":" P2021-092 \/ 2022 0970 266 000","project_id_year":2021,"project_id_index":26,"ices_scientist":"","principal_investigators":null,"knowledge_user":"","client":"","objectives":"","results":"","availability_of_results":"","pia_approved":null,"infographic":"","sitecore_item_id":"","sitecore_item_name":"","sitecore_field_values":""},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Mantle cell lymphoma (MCL): associated burden of illness and healthcare utilization in Ontario | ICES<\/title>\n<meta name=\"description\" content=\"Client: IQVIA Solutions Canada Inc.Project ID: P2021-092 \/ 2022 0970 266 000 Research Question\/Objectives: MCL is generally considered incurable, and a\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/mantle-cell-lymphoma-mcl-associated-burden-of-illness-and-health-care-utilization-in-ontario\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mantle cell lymphoma (MCL): associated burden of illness and healthcare utilization in Ontario | ICES\" \/>\n<meta property=\"og:description\" content=\"Client: IQVIA Solutions Canada Inc.Project ID: P2021-092 \/ 2022 0970 266 000 Research Question\/Objectives: MCL is generally considered incurable, and a\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/mantle-cell-lymphoma-mcl-associated-burden-of-illness-and-health-care-utilization-in-ontario\/\" \/>\n<meta property=\"og:site_name\" content=\"ICES\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ICESOntario\/\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-28T17:06:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/private-sector-projects\\\/mantle-cell-lymphoma-mcl-associated-burden-of-illness-and-health-care-utilization-in-ontario\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/private-sector-projects\\\/mantle-cell-lymphoma-mcl-associated-burden-of-illness-and-health-care-utilization-in-ontario\\\/\",\"name\":\"Mantle cell lymphoma (MCL): associated burden of illness and healthcare utilization in Ontario | ICES\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\"},\"datePublished\":\"2023-05-26T02:10:53+00:00\",\"dateModified\":\"2025-02-28T17:06:12+00:00\",\"description\":\"Client: IQVIA Solutions Canada Inc.Project ID: P2021-092 \\\/ 2022 0970 266 000 Research Question\\\/Objectives: MCL is generally considered incurable, and a\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/private-sector-projects\\\/mantle-cell-lymphoma-mcl-associated-burden-of-illness-and-health-care-utilization-in-ontario\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/private-sector-projects\\\/mantle-cell-lymphoma-mcl-associated-burden-of-illness-and-health-care-utilization-in-ontario\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/private-sector-projects\\\/mantle-cell-lymphoma-mcl-associated-burden-of-illness-and-health-care-utilization-in-ontario\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Private Sector Projects\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/private-sector-projects\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Mantle cell lymphoma (MCL): associated burden of illness and healthcare utilization in Ontario\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"name\":\"ICES\",\"description\":\"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\"},\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\",\"name\":\"ICES\",\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"contentUrl\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"width\":\"676\",\"height\":\"618\",\"caption\":\"ICES\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ICESOntario\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ices-research-institute\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mantle cell lymphoma (MCL): associated burden of illness and healthcare utilization in Ontario | ICES","description":"Client: IQVIA Solutions Canada Inc.Project ID: P2021-092 \/ 2022 0970 266 000 Research Question\/Objectives: MCL is generally considered incurable, and a","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/mantle-cell-lymphoma-mcl-associated-burden-of-illness-and-health-care-utilization-in-ontario\/","og_locale":"fr_FR","og_type":"article","og_title":"Mantle cell lymphoma (MCL): associated burden of illness and healthcare utilization in Ontario | ICES","og_description":"Client: IQVIA Solutions Canada Inc.Project ID: P2021-092 \/ 2022 0970 266 000 Research Question\/Objectives: MCL is generally considered incurable, and a","og_url":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/mantle-cell-lymphoma-mcl-associated-burden-of-illness-and-health-care-utilization-in-ontario\/","og_site_name":"ICES","article_publisher":"https:\/\/www.facebook.com\/ICESOntario\/","article_modified_time":"2025-02-28T17:06:12+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/mantle-cell-lymphoma-mcl-associated-burden-of-illness-and-health-care-utilization-in-ontario\/","url":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/mantle-cell-lymphoma-mcl-associated-burden-of-illness-and-health-care-utilization-in-ontario\/","name":"Mantle cell lymphoma (MCL): associated burden of illness and healthcare utilization in Ontario | ICES","isPartOf":{"@id":"https:\/\/www.ices.on.ca\/fr\/#website"},"datePublished":"2023-05-26T02:10:53+00:00","dateModified":"2025-02-28T17:06:12+00:00","description":"Client: IQVIA Solutions Canada Inc.Project ID: P2021-092 \/ 2022 0970 266 000 Research Question\/Objectives: MCL is generally considered incurable, and a","breadcrumb":{"@id":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/mantle-cell-lymphoma-mcl-associated-burden-of-illness-and-health-care-utilization-in-ontario\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/mantle-cell-lymphoma-mcl-associated-burden-of-illness-and-health-care-utilization-in-ontario\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/mantle-cell-lymphoma-mcl-associated-burden-of-illness-and-health-care-utilization-in-ontario\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ices.on.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Private Sector Projects","item":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/"},{"@type":"ListItem","position":3,"name":"Mantle cell lymphoma (MCL): associated burden of illness and healthcare utilization in Ontario"}]},{"@type":"WebSite","@id":"https:\/\/www.ices.on.ca\/fr\/#website","url":"https:\/\/www.ices.on.ca\/fr\/","name":"ICES","description":"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE","publisher":{"@id":"https:\/\/www.ices.on.ca\/fr\/#organization"},"alternateName":"Institute for Clinical Evaluative Sciences","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ices.on.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ices.on.ca\/fr\/#organization","name":"ICES","alternateName":"Institute for Clinical Evaluative Sciences","url":"https:\/\/www.ices.on.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","contentUrl":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","width":"676","height":"618","caption":"ICES"},"image":{"@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ICESOntario\/","https:\/\/www.linkedin.com\/company\/ices-research-institute\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/private_project\/14633","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/private_project"}],"about":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/types\/private_project"}],"wp:attachment":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/media?parent=14633"}],"wp:term":[{"taxonomy":"organization_type","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/organization_type?post=14633"},{"taxonomy":"project_status","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/project_status?post=14633"},{"taxonomy":"response_type","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/response_type?post=14633"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}